ORIGINAL ARTICLES

Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study

S Kusaka¹, C Shima¹, K Wada², H Arahori², H Shimojyo¹, T Sato¹ and T Fujikado¹

¹ Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
² Department of Pediatrics, Osaka University Medical School, Osaka, Japan

Correspondence to:
Dr S Kusaka, Department of Ophthalmology, E-7, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565–0871, Japan; skusaka{at}ophthal.med.osaka-u.ac.jp

Aim: The aim of the study was to evaluate the short-term efficacy of intravitreal injections of bevacizumab for severe retinopathy of prematurity (ROP).

Methods: A retrospective chart review was conducted of 23 consecutive eyes (stage 3, three eyes; 4A, 18 eyes; 4B, two eyes) of 14 patients with vascularly active ROP considered at high risk for progression or development of tractional retinal detachment despite conventional laser ablation therapy. Patients received an intravitreal injection of bevacizumab (0.5 mg), either as the initial treatment (15 eyes) or at the end of vitrectomy (eight eyes).

Results: After injection of bevacizumab as the initial treatment, reduced neovascular activity was seen on fluorescein angiography in 14 of 15 eyes. In three eyes, a tractional retinal detachment developed or progressed after bevacizumab injection. No other ocular or systemic adverse effects were identified. Vitrectomy was performed in 20 eyes and the retina was reattached after one surgery in 18 eyes. Multiple surgeries were necessary in two eyes, resulting in retinal reattachment.

Conclusion: There results suggest that intravitreal injection of bevacizumab seems to be associated with reduced neovascularisation without apparent ocular or systemic adverse effects, and is thus beneficial for treating severe ROP that is refractory to conventional laser therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Anti-vascular endothelial growth factor and retinopathy of prematurity

Jonathan E Sears
Br. J. Ophthalmol. 2008 92: 1437-1438. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Guma, M., Rius, J., Duong-Polk, K. X., Haddad, G. G., Lindsey, J. D., Karin, M. (2009). Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc. Natl. Acad. Sci. USA 106: 8760-8765 [Abstract] [Full Text]  
• Shima, C., Kusaka, S., Kondo, H., Hasebe, H., Fujikado, T., Tano, Y. (2009). Lens-Sparing Vitrectomy Effective for Reattachment of Newly Developed Falciform Retinal Detachment in a Patient With Norrie Disease. Arch Ophthalmol 127: 579-580 [Full Text]  
• Sears, J. E (2008). Anti-vascular endothelial growth factor and retinopathy of prematurity. Br. J. Ophthalmol. 92: 1437-1438 [Full Text]